Stock 3218 UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Universal Vision Biotechnology Co., Ltd.

Equities

3218

TW0003218004

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
256 TWD -0.97% Intraday chart for Universal Vision Biotechnology Co., Ltd. +8.47% -7.58%
Mar. 14 Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 13 Universal Vision Biotechnology Co., Ltd. Declares Cash Dividend, Payable on May 20, 2024 CI

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • With an enterprise value anticipated at 4.32 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. Stock Universal Vision Biotechnology Co., Ltd.
-7.58% 666M -
ESSILORLUXOTTICA Stock EssilorLuxottica
+10.74% 96.96B
B
THE COOPER COMPANIES, INC. Stock The Cooper Companies, Inc.
-5.14% 17.82B
B-
AUTEK CHINA INC. Stock Autek China Inc.
-16.61% 2.33B
D+
WARBY PARKER INC. Stock Warby Parker Inc.
-12.77% 1.42B
C+
PEGAVISION CORPORATION Stock Pegavision Corporation
+32.16% 1.26B -
MINGYUE OPTICAL LENS CO.,LTD. Stock Mingyue Optical Lens Co.,Ltd.
-34.97% 755M -
MENICON CO., LTD. Stock Menicon Co., Ltd.
-36.42% 737M
B-
VIZIONFOCUS INC. Stock Vizionfocus Inc.
+25.66% 501M - -
VISCO VISION INC. Stock Visco Vision Inc.
+16.82% 491M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 3218 Stock
  4. Ratings Universal Vision Biotechnology Co., Ltd.